Laboratory Co. of America (LH) Financials

$248.44 +0.79 (+0.32%)

As of 11:27 AM Eastern

Annual Income Statements for Laboratory Co. of America

This table shows Laboratory Co. of America's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	438	712	1,227	884	824	1,556	2,377	1,279	418	746
Consolidated Net Income / (Loss)	439	713	1,233	884	825	1,557	2,380	1,281	419	747
Net Income / (Loss) Continuing Operations	439	713	1,233	884	825	1,557	2,198	1,004	380	747
Total Pre-Tax Income	726	1,074	1,078	1,268	1,105	2,219	2,888	1,237	569	960
Total Operating Income	997	1,271	1,305	1,326	1,330	2,445	3,049	1,437	726	1,087
Total Gross Profit	2,903	2,854	3,092	3,176	3,253	4,953	4,992	3,709	3,365	3,624
Total Revenue	8,680	9,553	10,308	11,333	11,555	13,979	13,136	11,864	12,162	13,009
Operating Revenue	8,680	9,553	10,308	11,333	11,555	13,979	13,136	11,864	12,162	13,009
Total Cost of Revenue	5,777	6,699	7,216	8,157	8,302	9,026	8,144	8,155	8,797	9,385
Operating Cost of Revenue	5,777	6,699	7,216	8,157	8,302	9,026	8,144	8,155	8,797	9,385
Total Operating Expenses	1,907	1,583	1,787	1,851	1,922	2,507	1,944	2,272	2,639	2,538
Selling, General & Admin Expense	1,628	1,346	1,499	1,571	1,625	1,729	1,690	1,763	2,021	2,230
Amortization Expense	165	180	217	232	243	275	230	194	220	256
Impairment Charge	-	-	-	0.00	-	462	0.00	262	349	5.30
Restructuring Charge	114	58	71	48	55	41	24	54	49	46
Total Other Income / (Expense), net	-271	-197	-228	-57	-225	-226	-161	-199	-157	-127
Interest Expense	275	219	235	244	241	207	212	180	200	208
Interest & Investment Income	12	9.60	13	19	19	13	35	13	27	21
Other Income / (Expense), net	-7.80	13	-6.00	168	-3.20	-32	16	-32	16	60
Income Tax Expense	287	361	-155	384	280	662	690	234	189	212
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	182	277	39	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	1.10	1.10	5.80	0.20	1.10	0.90	2.20	1.50	1.20	1.10
Basic Earnings per Share	-	-	-	-	-	-	$24.60	$14.05	$4.80	$8.89
Weighted Average Basic Shares Outstanding	98.80M	102.50M	102.40M	101.40M	97.30M	195.20M	93.40M	88.50M	84.10M	83.70M
Diluted Earnings per Share	-	-	-	-	-	-	$24.39	$13.97	$4.77	$8.84
Weighted Average Diluted Shares Outstanding	98.80M	102.50M	102.40M	101.40M	97.30M	195.20M	93.40M	88.50M	84.10M	83.70M
Weighted Average Basic & Diluted Shares Outstanding	98.80M	102.50M	102.40M	101.40M	97.30M	195.20M	93.40M	88.50M	84.10M	83.70M
Cash Dividends to Common per Share	-	-	-	-	-	-	-	$2.16	$2.88	$2.88

This table shows Laboratory Co. of America's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	353	76	213	189	183	-167	228	205	169	143	213
Consolidated Net Income / (Loss)	353	76	213	189	184	-167	228	206	170	144	213
Net Income / (Loss) Continuing Operations	277	-34	208	155	184	-167	228	206	170	144	213
Total Pre-Tax Income	316	-78	272	205	239	-147	297	268	211	184	275
Total Operating Income	374	-54	330	266	252	-123	321	295	254	217	326
Total Gross Profit	886	647	850	842	851	821	897	926	904	896	948
Total Revenue	2,867	2,175	3,038	3,034	3,057	3,033	3,177	3,221	3,282	3,329	3,345
Operating Revenue	2,867	2,175	3,038	3,034	3,057	3,033	3,177	3,221	3,282	3,329	3,345
Total Cost of Revenue	1,981	1,527	2,188	2,192	2,206	2,212	2,279	2,295	2,378	2,433	2,397
Operating Cost of Revenue	1,981	1,527	2,188	2,192	2,206	2,212	2,279	2,295	2,378	2,433	2,397
Total Operating Expenses	512	702	520	576	599	944	576	632	650	680	622
Selling, General & Admin Expense	453	413	457	506	526	533	508	558	569	595	546
Amortization Expense	49	28	53	52	56	59	60	62	64	70	70
Impairment Charge	0.00	261	2.20	2.80	10	334	2.50	0.00	0.00	2.80	0.00
Restructuring Charge	10	-0.10	7.50	16	7.50	18	5.00	12	18	11	6.40
Total Other Income / (Expense), net	-59	-24	-58	-61	-14	-24	-24	-27	-44	-33	-51
Interest Expense	46	49	51	50	50	49	47	48	50	63	56
Interest & Investment Income	5.40	-0.10	0.10	5.40	16	6.30	3.00	1.00	2.60	14	6.20
Other Income / (Expense), net	-18	25	-6.90	-17	21	18	20	20	4.30	16	-1.00
Income Tax Expense	38	-44	64	50	55	20	69	62	41	40	62
Net Income / (Loss) Attributable to Noncontrolling Interest	0.40	0.30	0.40	0.20	0.30	0.30	0.30	0.30	0.30	0.20	0.20
Basic Earnings per Share	$3.91	$0.98	$2.41	$2.13	$2.12	($1.86)	$2.71	$2.44	$2.02	$1.72	$2.54
Weighted Average Basic Shares Outstanding	88.60M	88.50M	88.60M	-	84.90M	84.10M	84.29M	83.96M	83.64M	83.70M	83.70M
Diluted Earnings per Share	$3.90	$0.97	$2.39	$2.12	$2.11	($1.85)	$2.69	$2.43	$2.00	$1.72	$2.52
Weighted Average Diluted Shares Outstanding	88.60M	88.50M	88.60M	-	84.90M	84.10M	84.29M	83.96M	83.64M	83.70M	83.70M
Weighted Average Basic & Diluted Shares Outstanding	88.60M	88.50M	88.60M	-	84.90M	84.10M	84.29M	83.96M	83.64M	83.70M	83.70M
Cash Dividends to Common per Share	-	-	-	-	-	-	-	-	-	-	$0.72

This table details how cash moves in and out of Laboratory Co. of America's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	136	-283	-117	480	-89	983	152	-555	158	982
Net Cash From Operating Activities	982	1,197	1,498	1,305	1,445	2,135	3,110	1,956	1,328	1,586
Net Cash From Continuing Operating Activities	982	1,197	1,498	1,675	1,445	2,135	2,846	1,765	1,202	1,586
Net Income / (Loss) Continuing Operations	439	713	1,233	884	825	1,557	2,198	1,004	380	747
Consolidated Net Income / (Loss)	439	713	1,233	884	825	1,557	2,380	1,281	419	747
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	182	277	39	0.00
Depreciation Expense	458	499	533	552	771	825	741	537	577	644
Non-Cash Adjustments To Reconcile Net Income	149	103	110	196	61	531	92	528	674	152
Changes in Operating Assets and Liabilities, net	-63	-118	-378	44	-213	-778	-184	185	-378	-34
Net Cash From Discontinued Operating Activities	-	-	-	-	-	-	263	191	125	0.00
Net Cash From Investing Activities	-3,995	-796	-2,229	207	-1,283	-643	-885	-1,652	-1,172	-1,367
Net Cash From Continuing Investing Activities	-3,995	-796	-2,229	207	-1,283	-643	-846	-1,600	-1,147	-1,367
Purchase of Property, Plant & Equipment	-256	-279	-313	-380	-400	-382	-422	-429	-454	-490
Acquisitions	-3,748	-561	-1,921	-140	-904	-308	-525	-1,181	-701	-894
Sale of Property, Plant & Equipment	0.60	31	5.50	50	7.70	42	87	1.40	0.60	2.00
Divestitures	8.00	14	0.00	658	0.00	3.10	0.00	1.60	0.00	15
Sale and/or Maturity of Investments	-	0.00	0.00	18	13	1.00	13	8.10	6.70	0.00
Net Cash From Discontinued Investing Activities	-	-	-	-	-	-	-39	-53	-25	0.00
Net Cash From Financing Activities	3,185	-671	593	-1,390	-253	-517	-2,066	-1,322	-59	780
Net Cash From Continuing Financing Activities	3,185	-671	593	-1,390	-253	-517	-2,066	-1,322	-1,559	780
Repayment of Debt	-602	-643	-2,401	-1,162	-1,727	-591	-1,402	-814	-2,808	-3,500
Repurchase of Common Equity	0.00	-44	-338	-700	-450	-100	-1,669	-1,100	-1,000	-250
Payment of Dividends	0.00	-2.10	-	-	-	-	-	-195	-254	-243
Issuance of Debt	3,960	140	3,342	467	1,900	117	1,000	787	2,488	4,764
Issuance of Common Equity	99	71	74	69	65	56	4.20	51	54	56
Other Financing Activities, net	-272	-192	-84	-64	-41	-	-	-51	-40	-46
Net Cash From Discontinued Financing Activities	-	-	-	-	-	-	0.00	0.00	1,500	0.00
Other Net Changes in Cash	-	-	-	-	-	-	-	-	-	-17

This table details how cash moves in and out of Laboratory Co. of America's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-659	508	-36	1,646	-1,312	-140	-438	166	1,252	1.40	-1,149
Net Cash From Operating Activities	374	654	121	351	276	580	-30	561	277	777	19
Net Cash From Continuing Operating Activities	253	607	186	162	276	580	-30	561	277	777	19
Net Income / (Loss) Continuing Operations	277	37	208	155	184	-167	228	206	170	144	213
Consolidated Net Income / (Loss)	353	76	213	189	184	-167	228	206	170	144	213
Depreciation Expense	176	1.40	183	188	189	18	199	201	210	34	215
Non-Cash Adjustments To Reconcile Net Income	8.60	478	62	26	10	576	15	11	7.50	119	31
Changes in Operating Assets and Liabilities, net	-208	579	-268	-207	-108	205	-471	143	-109	404	-441
Net Cash From Investing Activities	-563	-273	-100	-254	-488	-331	-393	-185	-579	-210	-336
Net Cash From Continuing Investing Activities	-543	-255	-84	-245	-488	-331	-393	-185	-579	-210	-336
Purchase of Property, Plant & Equipment	-83	-99	-78	-103	-105	-167	-134	-128	-116	-112	-126
Acquisitions	-460	-162	-5.90	-141	-390	-164	-273	-57	-464	-101	-211
Sale of Property, Plant & Equipment	0.10	0.20	0.10	0.10	0.10	0.30	0.10	0.10	0.40	1.40	0.50
Divestitures	0.30	0.90	0.00	-	6.70	-6.70	14	-	-	1.60	0.00
Net Cash From Financing Activities	-452	-373	-61	1,545	-1,097	-447	-12	-210	1,548	-547	-840
Net Cash From Continuing Financing Activities	-452	-373	-61	-64	-988	-447	-12	-210	1,548	-547	-840
Repayment of Debt	-	-814	-828	-593	-458	-929	-211	-721	-2,132	-437	-1,068
Payment of Dividends	-65	-64	-64	-65	-64	-61	-62	-60	-61	-60	-62
Issuance of Debt	-	787	828	593	548	520	253	699	3,812	-	290
Issuance of Common Equity	32	-	28	27	-	-	27	-	26	3.20	26
Other Financing Activities, net	-19	18	-24	-26	-4.50	15	-19	-27	-23	22	-26
Effect of Exchange Rate Changes	-17	12	3.00	3.30	-2.80	6.40	-2.90	-0.30	5.70	-	7.90

This table presents Laboratory Co. of America's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	14,105	14,247	16,673	16,185	18,046	20,072	20,385	20,155	16,725	18,379
Total Current Assets	2,621	2,479	2,734	2,835	2,981	5,125	5,331	4,625	3,765	4,807
Cash & Equivalents	716	434	317	427	338	1,321	1,473	321	537	1,519
Accounts Receivable	1,375	1,519	1,848	1,862	2,025	3,017	2,978	1,997	2,099	2,097
Inventories, net	191	205	227	237	245	423	401	471	475	493
Prepaid Expenses	339	321	309	309	374	365	478	610	655	698
Plant, Property, & Equipment, net	1,747	1,719	1,707	1,740	2,637	2,730	2,815	2,794	2,912	3,045
Total Noncurrent Assets	9,734	10,048	11,843	11,610	12,429	12,217	12,240	12,736	10,048	10,527
Long-Term Investments	58	58	58	61	85	74	61	66	27	16
Goodwill	6,202	6,424	7,401	7,360	7,865	7,752	7,959	6,124	6,143	6,370
Intangible Assets	3,324	3,401	4,166	3,911	4,035	3,961	3,736	3,124	3,342	3,489
Other Noncurrent Operating Assets	150	165	218	276	435	410	463	378	537	652
Total Liabilities & Shareholders' Equity	14,105	14,247	16,673	16,185	18,046	20,072	20,385	20,155	16,725	18,379
Total Liabilities	9,145	8,726	9,762	9,195	10,459	10,614	10,091	10,059	8,835	10,313
Total Current Liabilities	1,701	1,828	2,166	1,879	2,656	3,079	2,783	3,079	3,225	3,330
Short-Term Debt	424	550	418	10	415	377	1.50	301	1,000	1,000
Accounts Payable	497	508	574	635	632	639	621	852	828	876
Accrued Expenses	633	594	793	870	942	1,358	1,404	787	804	871
Current Deferred Revenue	146	176	381	356	451	507	559	311	422	392
Other Current Liabilities	-	-	-	7.90	215	199	198	170	172	191
Total Noncurrent Liabilities	7,444	6,898	7,596	7,316	7,804	7,536	7,309	6,980	5,609	6,982
Long-Term Debt	5,940	5,300	6,345	5,991	5,790	5,419	5,417	5,039	4,055	5,331
Capital Lease Obligations	-	-	-	51	-	-	-	-	79	74
Noncurrent Deferred & Payable Income Tax Liabilities	1,181	1,206	876	940	943	829	763	543	418	383
Other Noncurrent Operating Liabilities	323	392	376	334	1,071	1,288	1,129	1,157	1,058	1,194
Commitments & Contingencies	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	20	21	21	-	16	14
Total Equity & Noncontrolling Interests	4,960	5,521	6,825	6,991	7,567	9,437	10,273	10,097	7,875	8,052
Total Preferred & Common Equity	4,960	5,521	6,825	6,971	7,567	9,437	10,273	10,097	7,875	8,052
Total Common Equity	4,960	5,521	6,825	6,971	7,567	9,437	10,273	10,097	7,875	8,052
Common Stock	2,001	2,159	2,023	1,463	36	119	8.50	8.10	46	10
Retained Earnings	4,224	4,956	6,196	7,080	7,904	9,479	10,457	10,582	7,888	8,303
Accumulated Other Comprehensive Income / (Loss)	-287	-581	-334	-463	-372	-162	-192	-493	-59	-262

This table presents Laboratory Co. of America's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Total Assets	19,826	20,155	17,719	16,886	16,725	16,531	16,712	18,613	18,379	17,604
Total Current Assets	4,372	4,625	5,121	3,954	3,765	3,457	3,571	4,910	4,807	3,790
Cash & Equivalents	410	321	1,931	728	537	99	265	1,517	1,519	369
Accounts Receivable	2,983	1,997	2,043	2,065	2,099	2,204	2,246	2,225	2,097	2,275
Inventories, net	468	471	488	461	475	475	442	483	493	488
Prepaid Expenses	512	610	660	700	655	678	618	685	698	658
Plant, Property, & Equipment, net	2,885	2,794	2,762	2,821	2,912	2,898	2,933	3,050	3,045	3,091
Total Noncurrent Assets	12,570	12,736	9,836	10,111	10,048	10,177	10,209	10,653	10,527	10,723
Long-Term Investments	64	66	67	40	27	18	18	17	16	168
Goodwill	8,218	6,124	6,182	6,332	6,143	6,219	6,220	6,482	6,370	6,421
Intangible Assets	3,808	3,124	3,154	3,276	3,342	3,394	3,332	3,541	3,489	3,487
Other Noncurrent Operating Assets	451	378	426	457	537	546	639	613	652	647
Total Liabilities & Shareholders' Equity	19,826	20,155	17,719	16,886	16,725	16,531	16,712	18,613	18,379	17,604
Total Liabilities	9,715	10,059	8,914	8,994	8,835	8,556	8,692	10,427	10,313	9,282
Total Current Liabilities	2,522	3,079	2,183	2,901	3,225	3,942	4,065	3,412	3,330	2,065
Short-Term Debt	-	301	301	991	1,000	2,042	2,020	1,400	1,000	0.40
Accounts Payable	766	852	713	691	828	696	761	661	876	718
Accrued Expenses	1,041	787	658	690	804	649	708	758	871	770
Current Deferred Revenue	531	311	350	361	422	378	388	403	392	388
Other Current Liabilities	185	170	161	169	172	178	189	191	191	188
Total Noncurrent Liabilities	7,212	6,980	6,750	6,112	5,609	4,630	4,642	7,030	6,982	7,218
Long-Term Debt	5,334	5,039	5,042	4,428	4,055	3,048	3,047	5,352	5,331	5,569
Capital Lease Obligations	-	-	-	-	79	-	-	-	74	67
Noncurrent Deferred & Payable Income Tax Liabilities	673	543	565	500	418	397	376	358	383	388
Other Noncurrent Operating Liabilities	1,205	1,157	1,144	1,185	1,058	1,185	1,218	1,320	1,194	1,194
Redeemable Noncontrolling Interest	-	-	-	-	16	-	-	-	14	14
Total Equity & Noncontrolling Interests	10,092	10,097	8,785	7,873	7,875	7,960	8,006	8,170	8,052	8,307
Total Preferred & Common Equity	10,092	10,097	8,785	7,873	7,875	7,960	8,006	8,170	8,052	8,307
Total Common Equity	10,092	10,097	8,785	7,873	7,875	7,960	8,006	8,170	8,052	8,307
Common Stock	8.20	8.10	103	12	46	90	20	7.60	10	43
Retained Earnings	10,845	10,582	8,836	8,070	7,888	8,055	8,178	8,276	8,303	8,456
Accumulated Other Comprehensive Income / (Loss)	-761	-493	-154	-209	-59	-185	-192	-113	-262	-192

This table displays calculated financial ratios and metrics derived from Laboratory Co. of America's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	44.39%	10.06%	7.90%	9.95%	1.95%	20.98%	-6.03%	-9.68%	2.51%	6.97%
EBITDA Growth	24.05%	23.19%	2.81%	11.63%	2.58%	54.33%	17.50%	-48.98%	-32.09%	35.80%
EBIT Growth	7.41%	29.74%	1.25%	14.95%	-11.14%	81.86%	26.97%	-54.17%	-47.23%	54.76%
NOPAT Growth	6.70%	40.07%	77.01%	-38.14%	7.49%	72.77%	35.22%	-49.79%	-58.35%	74.40%
Net Income Growth	-14.42%	62.50%	72.94%	-28.31%	-6.68%	88.75%	52.83%	-46.18%	-67.27%	78.22%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-42.72%	-65.86%	85.32%
Operating Cash Flow Growth	32.94%	21.85%	25.14%	-12.86%	10.67%	47.80%	45.63%	-37.10%	-32.12%	19.44%
Free Cash Flow Firm Growth	-1,309.92%	110.83%	-198.18%	346.58%	-85.65%	587.25%	63.06%	82.88%	-107.92%	227.27%
Invested Capital Growth	102.80%	3.13%	18.37%	-2.49%	6.49%	3.66%	2.31%	-17.59%	6.63%	3.83%
Revenue Q/Q Growth	9.98%	0.41%	4.09%	0.38%	1.46%	12.35%	-20.65%	10.25%	7.60%	2.33%
EBITDA Q/Q Growth	5.00%	4.56%	2.88%	-3.45%	7.74%	42.29%	-20.73%	-22.08%	-4.28%	24.60%
EBIT Q/Q Growth	1.45%	5.41%	2.90%	-4.21%	6.65%	63.22%	-20.70%	-26.75%	-9.23%	41.70%
NOPAT Q/Q Growth	0.84%	5.28%	77.57%	-36.13%	3.63%	72.98%	-19.12%	-27.51%	-24.10%	62.96%
Net Income Q/Q Growth	-2.16%	8.21%	74.38%	-37.57%	9.13%	84.11%	-13.93%	-27.15%	-36.72%	71.08%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-25.53%	-37.15%	67.74%
Operating Cash Flow Q/Q Growth	21.06%	7.69%	6.76%	-5.68%	6.13%	10.61%	-2.42%	-2.20%	-5.28%	14.23%
Free Cash Flow Firm Q/Q Growth	18.37%	-71.83%	49.01%	-21.45%	-45.98%	13.10%	-13.80%	635.63%	-109.44%	207.05%
Invested Capital Q/Q Growth	-12.76%	-1.71%	-0.17%	-1.61%	-0.14%	4.24%	2.42%	-21.85%	-0.51%	-3.37%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	33.45%	29.88%	29.99%	28.03%	28.15%	35.43%	38.01%	31.26%	27.67%	27.86%
EBITDA Margin	16.67%	18.66%	17.78%	18.05%	18.16%	23.17%	28.97%	16.36%	10.84%	13.76%
Operating Margin	11.48%	13.30%	12.66%	11.70%	11.51%	17.49%	23.21%	12.11%	5.97%	8.35%
EBIT Margin	11.39%	13.43%	12.60%	13.18%	11.48%	17.26%	23.33%	11.84%	6.09%	8.82%
Profit (Net Income) Margin	5.05%	7.46%	11.96%	7.80%	7.14%	11.14%	18.11%	10.79%	3.45%	5.74%
Tax Burden Percent	60.43%	66.40%	114.42%	69.69%	74.66%	70.16%	82.40%	103.49%	73.69%	77.86%
Interest Burden Percent	73.41%	83.67%	82.94%	84.93%	83.26%	91.95%	94.24%	88.12%	76.76%	83.66%
Effective Tax Rate	39.57%	33.60%	-14.42%	30.31%	25.34%	29.84%	23.90%	18.90%	33.13%	22.14%
Return on Invested Capital (ROIC)	7.65%	7.88%	12.58%	7.27%	7.66%	12.60%	16.55%	9.01%	4.02%	6.66%
ROIC Less NNEP Spread (ROIC-NNEP)	3.53%	5.49%	8.01%	6.58%	4.70%	9.48%	17.98%	13.23%	1.88%	4.57%
Return on Net Nonoperating Assets (RNNOA)	3.60%	5.73%	7.40%	5.53%	3.66%	5.67%	7.54%	3.55%	0.64%	2.70%
Return on Equity (ROE)	11.25%	13.60%	19.97%	12.80%	11.32%	18.27%	24.09%	12.56%	4.66%	9.36%
Cash Return on Invested Capital (CROIC)	-60.25%	4.80%	-4.25%	9.78%	1.38%	9.01%	14.27%	28.29%	-2.40%	2.90%
Operating Return on Assets (OROA)	9.24%	9.05%	8.40%	9.09%	7.75%	12.66%	15.15%	6.93%	4.02%	6.53%
Return on Assets (ROA)	4.10%	5.03%	7.97%	5.38%	4.82%	8.17%	11.76%	6.32%	2.27%	4.26%
Return on Common Equity (ROCE)	11.25%	13.60%	19.97%	12.78%	11.29%	18.23%	24.04%	12.55%	4.66%	9.35%
Return on Equity Simple (ROE_SIMPLE)	8.84%	12.91%	18.06%	12.68%	10.90%	16.50%	23.16%	12.68%	5.32%	9.28%
Net Operating Profit after Tax (NOPAT)	602	844	1,493	924	993	1,716	2,320	1,165	485	846
NOPAT Margin	6.94%	8.83%	14.49%	8.15%	8.59%	12.27%	17.66%	9.82%	3.99%	6.50%
Net Nonoperating Expense Percent (NNEP)	4.12%	2.39%	4.57%	0.69%	2.96%	3.12%	-1.43%	-4.23%	2.14%	2.10%
Return On Investment Capital (ROIC_SIMPLE)	5.32%	7.42%	10.99%	7.08%	7.21%	11.26%	14.79%	7.55%	3.73%	5.85%
Cost of Revenue to Revenue	66.55%	70.12%	70.01%	71.97%	71.85%	64.57%	61.99%	68.74%	72.33%	72.14%
SG&A Expenses to Revenue	18.76%	14.08%	14.54%	13.86%	14.06%	12.37%	12.87%	14.86%	16.62%	17.14%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	21.96%	16.58%	17.33%	16.33%	16.64%	17.94%	14.80%	19.15%	21.70%	19.51%
Earnings before Interest and Taxes (EBIT)	989	1,283	1,299	1,493	1,327	2,413	3,064	1,404	741	1,147
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,447	1,782	1,832	2,046	2,098	3,238	3,805	1,942	1,318	1,790
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.49	2.37	2.35	1.81	2.14	2.07	2.89	2.04	2.52	2.51
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	24.26	0.00	0.00
Price to Revenue (P/Rev)	1.42	1.37	1.56	1.11	1.40	1.40	2.26	1.74	1.63	1.56
Price to Earnings (P/E)	28.23	18.34	13.07	14.25	19.69	12.58	12.49	16.11	47.52	27.13
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.94%
Earnings Yield	3.54%	5.45%	7.65%	7.02%	5.08%	7.95%	8.01%	6.21%	2.10%	3.69%
Enterprise Value to Invested Capital (EV/IC)	1.70	1.69	1.74	1.45	1.65	1.73	2.37	2.19	1.96	1.94
Enterprise Value to Revenue (EV/Rev)	2.07	1.93	2.18	1.60	1.91	1.72	2.56	2.15	2.01	1.93
Enterprise Value to EBITDA (EV/EBITDA)	12.40	10.33	12.24	8.88	10.50	7.41	8.83	13.16	18.54	14.03
Enterprise Value to EBIT (EV/EBIT)	18.14	14.35	17.26	12.17	16.60	9.94	10.96	18.20	32.99	21.90
Enterprise Value to NOPAT (EV/NOPAT)	29.79	21.83	15.01	19.67	22.18	13.99	14.48	21.94	50.39	29.69
Enterprise Value to Operating Cash Flow (EV/OCF)	18.27	15.38	14.97	13.92	15.24	11.24	10.80	13.07	18.41	15.84
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	35.84	0.00	14.61	123.37	19.56	16.80	6.99	0.00	68.13
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.28	1.06	0.99	0.87	0.82	0.61	0.53	0.53	0.65	0.79
Long-Term Debt to Equity	1.20	0.96	0.93	0.86	0.76	0.57	0.53	0.50	0.52	0.67
Financial Leverage	1.02	1.04	0.92	0.84	0.78	0.60	0.42	0.27	0.34	0.59
Leverage Ratio	2.75	2.71	2.50	2.38	2.35	2.24	2.05	1.99	2.05	2.20
Compound Leverage Factor	2.02	2.26	2.08	2.02	1.96	2.06	1.93	1.75	1.57	1.84
Debt to Total Capital	56.20%	51.44%	49.77%	46.40%	44.99%	38.00%	34.48%	34.59%	39.41%	44.26%
Short-Term Debt to Total Capital	3.74%	4.83%	3.07%	0.08%	3.01%	2.47%	0.01%	1.95%	7.68%	6.91%
Long-Term Debt to Total Capital	52.46%	46.61%	46.70%	46.33%	41.98%	35.53%	34.47%	32.64%	31.74%	37.35%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.15%	0.15%	0.14%	0.13%	0.00%	0.12%	0.10%
Common Equity to Total Capital	43.80%	48.56%	50.23%	53.45%	54.86%	61.87%	65.39%	65.41%	60.47%	55.64%
Debt to EBITDA	4.40	3.28	3.69	2.96	2.96	1.79	1.42	2.75	3.89	3.58
Net Debt to EBITDA	3.86	3.01	3.49	2.72	2.76	1.36	1.02	2.55	3.47	2.72
Long-Term Debt to EBITDA	4.11	2.97	3.46	2.95	2.76	1.67	1.42	2.60	3.14	3.02
Debt to NOPAT	10.57	6.93	4.53	6.55	6.25	3.38	2.34	4.58	10.58	7.57
Net Debt to NOPAT	9.28	6.35	4.28	6.02	5.82	2.57	1.67	4.25	9.42	5.76
Long-Term Debt to NOPAT	9.86	6.28	4.25	6.54	5.83	3.16	2.33	4.33	8.52	6.39
Altman Z-Score	2.16	2.41	2.42	2.51	2.45	2.98	3.77	2.87	2.92	2.82
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.14%	0.27%	0.24%	0.21%	0.10%	0.09%	0.19%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.54	1.36	1.26	1.51	1.12	1.66	1.92	1.50	1.17	1.44
Quick Ratio	1.23	1.07	1.00	1.22	0.89	1.41	1.60	0.75	0.82	1.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4,744	514	-504	1,244	179	1,227	2,000	3,658	-290	369
Operating Cash Flow to CapEx	384.95%	482.51%	487.35%	395.94%	368.08%	628.77%	930.46%	457.09%	293.09%	325.03%
Free Cash Flow to Firm to Interest Expense	-17.26	2.35	-2.15	5.09	0.74	5.92	9.44	20.35	-1.45	1.77
Operating Cash Flow to Interest Expense	3.57	5.46	6.37	5.35	6.00	10.30	14.68	10.88	6.65	7.61
Operating Cash Flow Less CapEx to Interest Expense	2.65	4.33	5.06	4.00	4.37	8.66	13.10	8.50	4.38	5.27
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.81	0.67	0.67	0.69	0.68	0.73	0.65	0.59	0.66	0.74
Accounts Receivable Turnover	7.93	6.60	6.12	6.11	5.94	5.54	4.38	4.77	5.94	6.20
Inventory Turnover	34.96	33.82	33.38	35.12	34.45	27.03	19.75	18.70	18.61	19.39
Fixed Asset Turnover	6.85	5.51	6.02	6.58	5.28	5.21	4.74	4.23	4.26	4.37
Accounts Payable Turnover	14.82	13.32	13.33	13.50	13.11	14.20	12.92	11.07	10.47	11.02
Days Sales Outstanding (DSO)	46.05	55.27	59.60	59.74	61.40	65.83	83.29	76.54	61.47	58.86
Days Inventory Outstanding (DIO)	10.44	10.79	10.94	10.39	10.60	13.51	18.48	19.51	19.61	18.82
Days Payable Outstanding (DPO)	24.63	27.40	27.37	27.04	27.85	25.70	28.24	32.98	34.85	33.12
Cash Conversion Cycle (CCC)	31.86	38.66	43.16	43.09	44.15	53.63	73.53	63.08	46.23	44.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	10,547	10,877	12,875	12,555	13,370	13,859	14,178	11,685	12,460	12,937
Invested Capital Turnover	1.10	0.89	0.87	0.89	0.89	1.03	0.94	0.92	1.01	1.02
Increase / (Decrease) in Invested Capital	5,346	330	1,998	-320	815	489	320	-2,493	775	477
Enterprise Value (EV)	17,945	18,415	22,421	18,173	22,023	23,999	33,597	25,555	24,448	25,122
Market Capitalization	12,355	13,057	16,034	12,590	16,220	19,577	29,692	20,602	19,863	20,237
Book Value per Share	$49.01	$53.60	$67.04	$69.09	$77.93	$96.89	$107.35	$113.96	$92.76	$96.27
Tangible Book Value per Share	($45.11)	($41.79)	($46.58)	($42.62)	($44.62)	($23.37)	($14.85)	$9.59	($18.96)	($21.60)
Total Capital	11,324	11,371	13,587	13,042	13,792	15,253	15,712	15,437	13,024	14,472
Total Debt	6,364	5,850	6,762	6,052	6,205	5,796	5,418	5,340	5,133	6,406
Total Long-Term Debt	5,940	5,300	6,345	6,042	5,790	5,419	5,417	5,039	4,133	5,406
Net Debt	5,590	5,358	6,387	5,565	5,783	4,401	3,884	4,954	4,569	4,871
Capital Expenditures (CapEx)	255	248	307	330	393	340	334	428	453	488
Debt-free, Cash-free Net Working Capital (DFCFNWC)	628	767	669	540	403	1,103	1,076	1,527	1,003	958
Debt-free Net Working Capital (DFNWC)	1,345	1,201	986	967	741	2,424	2,549	1,848	1,540	2,477
Net Working Capital (NWC)	921	651	568	957	325	2,047	2,548	1,547	540	1,476
Net Nonoperating Expense (NNE)	164	131	261	40	168	159	-59	-116	66	99
Net Nonoperating Obligations (NNO)	5,587	5,356	6,050	5,565	5,783	4,401	3,884	1,588	4,569	4,871
Total Depreciation and Amortization (D&A)	458	499	533	552	771	825	741	537	577	644
Debt-free, Cash-free Net Working Capital to Revenue	7.24%	8.03%	6.49%	4.76%	3.49%	7.89%	8.19%	12.87%	8.25%	7.36%
Debt-free Net Working Capital to Revenue	15.49%	12.57%	9.56%	8.53%	6.41%	17.34%	19.41%	15.58%	12.66%	19.04%
Net Working Capital to Revenue	10.61%	6.82%	5.51%	8.44%	2.82%	14.64%	19.39%	13.04%	4.44%	11.35%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$4.80	$8.89
Adjusted Weighted Average Basic Shares Outstanding	0.00	102.30M	101.90M	98.60M	97.30M	97.60M	0.00	88.50M	84.10M	83.70M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$4.77	$8.84
Adjusted Weighted Average Diluted Shares Outstanding	0.00	102.30M	101.90M	98.60M	97.30M	97.60M	0.00	88.50M	84.10M	83.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	102.30M	101.90M	98.60M	97.30M	97.60M	0.00	88.50M	84.10M	83.70M
Normalized Net Operating Profit after Tax (NOPAT)	671	882	963	957	1,034	2,068	2,338	1,421	751	886
Normalized NOPAT Margin	7.73%	9.24%	9.34%	8.45%	8.95%	14.80%	17.80%	11.98%	6.18%	6.81%
Pre Tax Income Margin	8.36%	11.24%	10.45%	11.19%	9.56%	15.88%	21.98%	10.43%	4.68%	7.38%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.60	5.86	5.53	6.12	5.51	11.64	14.47	7.81	3.71	5.51
NOPAT to Interest Expense	2.19	3.85	6.35	3.78	4.13	8.27	10.95	6.48	2.43	4.06
EBIT Less CapEx to Interest Expense	2.67	4.72	4.22	4.77	3.88	10.00	12.89	5.43	1.44	3.16
NOPAT Less CapEx to Interest Expense	1.26	2.72	5.04	2.43	2.50	6.64	9.38	4.10	0.16	1.72
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.29%	0.00%	0.00%	0.00%	0.00%	0.00%	15.24%	60.59%	32.54%
Augmented Payout Ratio	0.00%	6.45%	27.42%	79.19%	54.55%	6.42%	70.12%	101.14%	299.14%	66.02%

This table displays calculated financial ratios and metrics derived from Laboratory Co. of America's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-29.43%	102.98%	-22.10%	3.79%	6.63%	39.49%	4.57%	6.17%	7.37%	9.76%	5.30%
EBITDA Growth	-48.55%	-105.32%	-43.09%	-20.45%	-13.01%	-211.87%	6.81%	18.04%	1.15%	407.73%	0.09%
EBIT Growth	-55.38%	-106.04%	-52.36%	-37.54%	-23.29%	-258.22%	5.70%	26.02%	-5.49%	322.66%	-4.78%
NOPAT Growth	-43.98%	-108.78%	-52.27%	-36.83%	-40.96%	-126.57%	-2.28%	12.30%	5.45%	296.78%	2.30%
Net Income Growth	-39.91%	-86.20%	-56.66%	-47.31%	-48.02%	-318.32%	7.03%	8.73%	-7.63%	186.09%	-6.70%
EPS Growth	-35.54%	-83.16%	-54.30%	-45.22%	-45.90%	-290.72%	12.55%	14.62%	-5.21%	192.97%	-6.32%
Operating Cash Flow Growth	-51.28%	-6.29%	-65.96%	-38.62%	-26.30%	-11.32%	-124.59%	59.68%	0.65%	34.09%	162.08%
Free Cash Flow Firm Growth	-2,112.83%	2,083.54%	-184.74%	2,240.94%	435.77%	-135.06%	95.34%	-184.68%	-125.13%	64.19%	57.43%
Invested Capital Growth	8.02%	-17.59%	0.00%	0.00%	-16.24%	6.63%	6.60%	0.00%	6.90%	3.83%	3.78%
Revenue Q/Q Growth	-1.92%	-24.15%	39.70%	-0.14%	0.76%	-0.77%	4.72%	1.39%	1.90%	1.44%	0.47%
EBITDA Q/Q Growth	-3.15%	-105.23%	1,918.35%	-13.57%	5.91%	-118.74%	722.72%	-4.48%	-9.25%	-42.99%	102.55%
EBIT Q/Q Growth	-10.74%	-108.19%	1,205.82%	-22.76%	9.62%	-138.26%	426.29%	-7.91%	-17.79%	-9.87%	39.54%
NOPAT Q/Q Growth	3.00%	-111.54%	765.28%	-20.13%	-3.74%	-144.30%	386.93%	-8.20%	-9.62%	-17.34%	49.17%
Net Income Q/Q Growth	-1.59%	-78.37%	179.19%	-11.35%	-2.91%	-190.85%	236.87%	-9.94%	-17.51%	-15.33%	48.33%
EPS Q/Q Growth	0.78%	-75.13%	146.39%	-11.30%	-0.47%	-187.68%	245.41%	-9.67%	-17.70%	-14.00%	46.51%
Operating Cash Flow Q/Q Growth	-34.71%	74.85%	-81.46%	189.93%	-21.60%	110.38%	-105.14%	1,982.89%	-50.58%	180.27%	-97.62%
Free Cash Flow Firm Q/Q Growth	-12.72%	414.37%	-583.76%	224.90%	-82.32%	-132.82%	35.64%	-2,167.58%	94.75%	53.23%	23.48%
Invested Capital Q/Q Growth	2.18%	-21.85%	3.82%	-100.00%	0.00%	-0.51%	3.79%	-1.10%	4.68%	-3.37%	3.73%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.91%	29.77%	27.98%	27.76%	27.85%	27.08%	28.25%	28.76%	27.56%	26.92%	28.34%
EBITDA Margin	18.55%	-1.28%	16.64%	14.40%	15.14%	-2.86%	17.00%	16.01%	14.26%	8.01%	16.16%
Operating Margin	13.05%	-2.49%	10.86%	8.78%	8.25%	-4.05%	10.11%	9.15%	7.74%	6.50%	9.75%
EBIT Margin	12.43%	-1.34%	10.63%	8.22%	8.94%	-3.45%	10.74%	9.76%	7.87%	7.00%	9.72%
Profit (Net Income) Margin	12.32%	3.51%	7.02%	6.23%	6.01%	-5.50%	7.19%	6.38%	5.17%	4.31%	6.37%
Tax Burden Percent	111.95%	-97.57%	78.33%	92.24%	76.92%	113.39%	76.77%	76.80%	80.53%	78.13%	77.40%
Interest Burden Percent	88.52%	268.15%	84.33%	82.20%	87.31%	140.63%	87.14%	85.17%	81.50%	78.92%	84.68%
Effective Tax Rate	12.11%	0.00%	23.47%	24.29%	23.08%	0.00%	23.23%	23.20%	19.47%	21.87%	22.60%
Return on Invested Capital (ROIC)	8.57%	-1.60%	15.07%	0.00%	5.22%	-2.85%	7.62%	13.73%	6.12%	5.20%	7.54%
ROIC Less NNEP Spread (ROIC-NNEP)	9.17%	2.58%	12.73%	0.00%	5.00%	-5.48%	7.18%	12.86%	5.41%	4.66%	6.76%
Return on Net Nonoperating Assets (RNNOA)	3.64%	0.69%	4.85%	0.00%	2.65%	-1.88%	3.57%	7.68%	3.33%	2.76%	4.18%
Return on Equity (ROE)	12.21%	-0.91%	19.92%	0.00%	7.87%	-4.73%	11.19%	21.41%	9.44%	7.96%	11.73%
Cash Return on Invested Capital (CROIC)	3.45%	28.29%	-185.28%	0.00%	22.33%	-2.40%	-2.53%	-192.00%	-2.66%	2.90%	2.76%
Operating Return on Assets (OROA)	6.58%	-0.79%	6.60%	0.00%	5.51%	-2.27%	7.72%	7.29%	5.64%	5.18%	7.50%
Return on Assets (ROA)	6.52%	2.06%	4.36%	0.00%	3.70%	-3.63%	5.16%	4.77%	3.70%	3.20%	4.92%
Return on Common Equity (ROCE)	12.21%	-0.91%	19.92%	0.00%	7.87%	-4.73%	11.19%	21.41%	9.44%	7.95%	11.72%
Return on Equity Simple (ROE_SIMPLE)	17.42%	0.00%	11.40%	0.00%	8.41%	0.00%	5.46%	5.63%	5.35%	0.00%	8.81%
Net Operating Profit after Tax (NOPAT)	329	-38	252	202	194	-86	247	226	205	169	252
NOPAT Margin	11.47%	-1.74%	8.31%	6.65%	6.35%	-2.83%	7.76%	7.03%	6.24%	5.08%	7.54%
Net Nonoperating Expense Percent (NNEP)	-0.60%	-4.18%	2.34%	0.00%	0.22%	2.63%	0.44%	0.87%	0.71%	0.54%	0.78%
Return On Investment Capital (ROIC_SIMPLE)	2.13%	-0.25%	1.79%	-	1.46%	-0.66%	1.89%	1.73%	1.37%	1.17%	1.81%
Cost of Revenue to Revenue	69.09%	70.23%	72.02%	72.24%	72.15%	72.92%	71.75%	71.24%	72.44%	73.08%	71.66%
SG&A Expenses to Revenue	15.81%	19.01%	15.05%	16.67%	17.19%	17.57%	16.00%	17.32%	17.32%	17.88%	16.32%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	17.87%	32.26%	17.13%	18.98%	19.59%	31.13%	18.13%	19.61%	19.81%	20.42%	18.59%
Earnings before Interest and Taxes (EBIT)	356	-29	323	249	273	-105	341	314	258	233	325
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	532	-28	506	437	463	-87	540	516	468	267	540
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.81	2.04	2.28	0.00	2.23	2.52	2.40	2.23	2.41	2.51	2.48
Price to Tangible Book Value (P/TBV)	0.00	24.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.70	1.74	1.82	1.90	1.55	1.63	1.55	1.43	1.55	1.56	1.56
Price to Earnings (P/E)	10.41	16.11	20.04	25.39	26.57	47.52	44.08	39.71	45.15	27.13	28.18
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.36%	0.65%	0.94%	1.24%
Earnings Yield	9.60%	6.21%	4.99%	3.94%	3.76%	2.10%	2.27%	2.52%	2.21%	3.69%	3.55%
Enterprise Value to Invested Capital (EV/IC)	1.55	2.19	1.93	0.00	1.77	1.96	1.86	1.77	1.86	1.94	1.92
Enterprise Value to Revenue (EV/Rev)	2.15	2.15	2.13	0.00	1.97	2.01	1.96	1.81	1.96	1.93	1.95
Enterprise Value to EBITDA (EV/EBITDA)	9.29	13.16	15.01	0.00	16.13	18.54	17.79	15.81	17.32	14.03	14.36
Enterprise Value to EBIT (EV/EBIT)	12.07	18.20	22.29	0.00	27.21	32.99	31.68	27.46	30.74	21.90	22.74
Enterprise Value to NOPAT (EV/NOPAT)	14.40	21.94	26.21	0.00	34.76	50.39	49.79	44.23	47.92	29.69	30.17
Enterprise Value to Operating Cash Flow (EV/OCF)	11.57	13.07	13.59	0.00	15.85	18.41	20.45	16.33	17.92	15.84	15.73
Enterprise Value to Free Cash Flow (EV/FCFF)	46.54	6.99	0.00	0.00	7.24	0.00	0.00	0.00	0.00	68.13	70.65
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.53	0.53	0.61	0.00	0.69	0.65	0.64	0.63	0.83	0.79	0.68
Long-Term Debt to Equity	0.53	0.50	0.57	0.00	0.56	0.52	0.38	0.38	0.66	0.67	0.68
Financial Leverage	0.40	0.27	0.38	0.00	0.53	0.34	0.50	0.60	0.62	0.59	0.62
Leverage Ratio	1.97	1.99	2.02	0.00	2.04	2.05	2.05	2.09	2.21	2.20	2.10
Compound Leverage Factor	1.75	5.33	1.70	0.00	1.78	2.88	1.78	1.78	1.80	1.74	1.78
Debt to Total Capital	34.58%	34.59%	37.82%	0.00%	40.77%	39.41%	39.00%	38.76%	45.25%	44.26%	40.38%
Short-Term Debt to Total Capital	0.00%	1.95%	2.13%	0.00%	7.46%	7.68%	15.65%	15.45%	9.38%	6.91%	0.00%
Long-Term Debt to Total Capital	34.58%	32.64%	35.69%	0.00%	33.31%	31.74%	23.36%	23.31%	35.87%	37.35%	40.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.12%	0.00%	0.00%	0.00%	0.10%	0.10%
Common Equity to Total Capital	65.42%	65.41%	62.18%	0.00%	59.23%	60.47%	61.00%	61.24%	54.75%	55.64%	59.52%
Debt to EBITDA	2.14	2.75	3.43	0.00	3.93	3.89	3.76	3.54	4.70	3.58	3.15
Net Debt to EBITDA	1.95	2.55	2.15	0.00	3.38	3.47	3.68	3.34	3.63	2.72	2.85
Long-Term Debt to EBITDA	2.14	2.60	3.23	0.00	3.21	3.14	2.25	2.13	3.72	3.02	3.15
Debt to NOPAT	3.32	4.58	5.99	0.00	8.48	10.58	10.53	9.90	13.00	7.57	6.61
Net Debt to NOPAT	3.02	4.25	3.75	0.00	7.28	9.42	10.29	9.35	10.05	5.76	5.98
Long-Term Debt to NOPAT	3.32	4.33	5.65	0.00	6.93	8.52	6.31	5.96	10.31	6.39	6.61
Altman Z-Score	2.61	2.64	2.93	0.00	2.64	2.75	2.80	2.69	2.58	2.66	2.93
Noncontrolling Interest Sharing Ratio	0.00%	0.10%	0.00%	0.00%	0.00%	0.09%	0.00%	0.00%	0.00%	0.19%	0.09%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.73	1.50	2.35	0.00	1.36	1.17	0.88	0.88	1.44	1.44	1.84
Quick Ratio	1.35	0.75	1.82	0.00	0.96	0.82	0.58	0.62	1.10	1.09	1.28
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-781	2,455	-11,879	14,836	2,623	-861	-554	-12,564	-659	-308	-236
Operating Cash Flow to CapEx	452.00%	660.87%	155.19%	340.50%	262.88%	347.27%	-22.29%	438.02%	240.29%	702.08%	14.74%
Free Cash Flow to Firm to Interest Expense	-16.87	50.11	-234.29	297.91	52.14	-17.64	-11.81	-263.94	-13.08	-4.86	-4.21
Operating Cash Flow to Interest Expense	8.07	13.34	2.39	7.06	5.48	11.88	-0.64	11.79	5.50	12.26	0.33
Operating Cash Flow Less CapEx to Interest Expense	6.29	11.32	0.85	4.98	3.39	8.46	-3.49	9.10	3.21	10.51	-1.91
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.53	0.59	0.62	0.00	0.62	0.66	0.72	0.75	0.72	0.74	0.77
Accounts Receivable Turnover	3.56	4.77	5.39	0.00	4.48	5.94	5.79	5.56	5.93	6.20	5.88
Inventory Turnover	15.84	18.70	15.74	0.00	17.47	18.61	18.46	20.35	19.41	19.39	19.73
Fixed Asset Turnover	3.86	4.23	3.98	0.00	3.96	4.26	4.35	4.26	4.33	4.37	4.40
Accounts Payable Turnover	9.70	11.07	10.76	0.00	11.14	10.47	12.62	11.82	13.56	11.02	13.45
Days Sales Outstanding (DSO)	102.40	76.54	67.76	0.00	81.50	61.47	63.01	65.66	61.58	58.86	62.03
Days Inventory Outstanding (DIO)	23.05	19.51	23.20	0.00	20.90	19.61	19.77	17.93	18.81	18.82	18.50
Days Payable Outstanding (DPO)	37.65	32.98	33.91	0.00	32.76	34.85	28.92	30.88	26.92	33.12	27.15
Cash Conversion Cycle (CCC)	87.80	63.08	57.05	0.00	69.64	46.23	53.85	52.72	53.47	44.56	53.38
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	14,953	11,685	12,131	0.00	12,524	12,460	12,932	12,790	13,388	12,937	13,420
Invested Capital Turnover	0.75	0.92	1.81	0.00	0.82	1.01	0.98	1.95	0.98	1.02	1.00
Increase / (Decrease) in Invested Capital	1,110	-2,493	12,131	-14,635	-2,429	775	801	12,790	864	477	488
Enterprise Value (EV)	23,143	25,555	23,395	0.00	22,221	24,448	24,063	22,634	24,880	25,122	25,710
Market Capitalization	18,282	20,602	20,049	21,090	17,570	19,863	19,091	17,850	19,663	20,237	20,597
Book Value per Share	$111.64	$113.96	$99.27	$0.00	$88.86	$92.76	$94.43	$94.98	$97.31	$96.27	$99.25
Tangible Book Value per Share	($21.39)	$9.59	($6.23)	$0.00	($19.58)	($18.96)	($19.61)	($18.35)	($22.07)	($21.60)	($19.13)
Total Capital	15,427	15,437	14,129	0.00	13,292	13,024	13,049	13,073	14,922	14,472	13,957
Total Debt	5,334	5,340	5,344	0.00	5,419	5,133	5,089	5,067	6,752	6,406	5,636
Total Long-Term Debt	5,334	5,039	5,042	0.00	4,428	4,133	3,048	3,047	5,352	5,406	5,635
Net Debt	4,861	4,954	3,346	0.00	4,651	4,569	4,972	4,784	5,218	4,871	5,098
Capital Expenditures (CapEx)	83	99	78	103	105	167	134	128	115	111	126
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,440	1,527	1,308	0.00	1,317	1,003	1,457	1,261	1,381	958	1,356
Debt-free Net Working Capital (DFNWC)	1,850	1,848	3,239	0.00	2,044	1,540	1,557	1,526	2,898	2,477	1,726
Net Working Capital (NWC)	1,850	1,547	2,938	0.00	1,053	540	-485	-493	1,498	1,476	1,725
Net Nonoperating Expense (NNE)	-24	-114	39	13	10	81	18	21	35	26	39
Net Nonoperating Obligations (NNO)	4,861	1,588	3,346	0.00	4,651	4,569	4,972	4,784	5,218	4,871	5,098
Total Depreciation and Amortization (D&A)	176	1.40	183	188	189	18	199	201	210	34	215
Debt-free, Cash-free Net Working Capital to Revenue	13.38%	12.87%	11.89%	0.00%	11.65%	8.25%	11.85%	10.10%	10.86%	7.36%	10.29%
Debt-free Net Working Capital to Revenue	17.19%	15.58%	29.44%	0.00%	18.09%	12.66%	12.65%	12.22%	22.79%	19.04%	13.09%
Net Working Capital to Revenue	17.19%	13.04%	26.70%	0.00%	9.32%	4.44%	-3.94%	-3.95%	11.78%	11.35%	13.09%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.91	$0.98	$0.00	$0.00	$2.12	($1.86)	$2.71	$2.44	$2.02	$1.72	$2.54
Adjusted Weighted Average Basic Shares Outstanding	88.60M	88.50M	0.00	0.00	84.90M	84.10M	84.29M	83.96M	83.64M	83.70M	83.70M
Adjusted Diluted Earnings per Share	$3.90	$0.97	$0.00	$0.00	$2.11	($1.85)	$2.69	$2.43	$2.00	$1.72	$2.52
Adjusted Weighted Average Diluted Shares Outstanding	88.60M	88.50M	0.00	0.00	84.90M	84.10M	84.29M	83.96M	83.64M	83.70M	83.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	88.60M	88.50M	0.00	0.00	84.90M	84.10M	84.29M	83.96M	83.64M	83.70M	83.70M
Normalized Net Operating Profit after Tax (NOPAT)	338	144	260	216	208	161	252	235	219	180	257
Normalized NOPAT Margin	11.77%	6.64%	8.55%	7.11%	6.79%	5.29%	7.95%	7.31%	6.68%	5.41%	7.69%
Pre Tax Income Margin	11.01%	-3.60%	8.96%	6.76%	7.81%	-4.85%	9.36%	8.31%	6.42%	5.52%	8.23%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.70	-0.60	6.37	5.01	5.44	-2.14	7.28	6.60	5.13	3.67	5.80
NOPAT to Interest Expense	7.10	-0.77	4.98	4.05	3.86	-1.76	5.26	4.76	4.06	2.67	4.51
EBIT Less CapEx to Interest Expense	5.91	-2.61	4.83	2.94	3.35	-5.56	4.43	3.91	2.84	1.93	3.56
NOPAT Less CapEx to Interest Expense	5.31	-2.79	3.44	1.98	1.77	-5.18	2.41	2.07	1.77	0.92	2.26
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	15.24%	25.91%	30.95%	38.72%	60.59%	57.97%	54.91%	55.90%	32.54%	33.15%
Augmented Payout Ratio	102.40%	101.14%	25.91%	115.08%	236.34%	299.14%	57.97%	298.98%	93.91%	66.02%	33.15%

Frequently Asked Questions About Laboratory Co. of America's Financials

When does Laboratory Co. of America's fiscal year end?

According to the most recent income statement we have on file, Laboratory Co. of America's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Laboratory Co. of America's net income changed over the last 9 years?

Laboratory Co. of America's net income appears to be on an upward trend, with a most recent value of $747.10 million in 2024, rising from $438.70 million in 2015. The previous period was $419.20 million in 2023. Find out what analysts predict for Laboratory Co. of America in the coming months.

What is Laboratory Co. of America's operating income?

Laboratory Co. of America's total operating income in 2024 was $1.09 billion, based on the following breakdown:

Total Gross Profit: $3.62 billion
Total Operating Expenses: $2.54 billion

How has Laboratory Co. of America revenue changed over the last 9 years?

Over the last 9 years, Laboratory Co. of America's total revenue changed from $8.68 billion in 2015 to $13.01 billion in 2024, a change of 49.9%.

How much debt does Laboratory Co. of America have?

Laboratory Co. of America's total liabilities were at $10.31 billion at the end of 2024, a 16.7% increase from 2023, and a 12.8% increase since 2015.

How much cash does Laboratory Co. of America have?

In the past 9 years, Laboratory Co. of America's cash and equivalents has ranged from $316.60 million in 2017 to $1.52 billion in 2024, and is currently $1.52 billion as of their latest financial filing in 2024.

How has Laboratory Co. of America's book value per share changed over the last 9 years?

Over the last 9 years, Laboratory Co. of America's book value per share changed from 49.01 in 2015 to 96.27 in 2024, a change of 96.4%.

Related Companies

This page (NYSE:LH) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Laboratory Co. of America (LH) Financials

Frequently Asked Questions About Laboratory Co. of America's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Laboratory Co. of America (LH) Financials

Annual Income Statements for Laboratory Co. of America

Quarterly Income Statements for Laboratory Co. of America

Annual Cash Flow Statements for Laboratory Co. of America

Quarterly Cash Flow Statements for Laboratory Co. of America

Annual Balance Sheets for Laboratory Co. of America

Quarterly Balance Sheets for Laboratory Co. of America

Annual Metrics and Ratios for Laboratory Co. of America

Quarterly Metrics and Ratios for Laboratory Co. of America

Frequently Asked Questions About Laboratory Co. of America's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools